Raymond Osarogiagbon, MD
Hematology & Oncology · Memphis, TNNPI 1831181247
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $84,722 of the $117,389 with a category attached, or 72.2%. 33 manufacturers reported payments, led by Astrazeneca UK Limited at 47.0% of the total. 2025 is the largest year on record at $37,482, more than ten times the $76 reported in 2019.
Across 124 payments — averaging $946.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$55K
- AstraZeneca$31K
- GE HealthCare$13K
- Genentech USA, Inc.$4K
- Genentech, Inc.$4K
- Daiichi Sankyo Inc.$3K
- plus $7K from 27 others
Across 25 payments — averaging $8635.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$205K
- Amgen$7K
- Merck$3K
What the payments were for
- Consulting fees$84,72272%
- Speaking & faculty fees$16,59014%
- Travel & lodging$12,21510%
- Food & beverage$3,8263%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 16 | $55,187 |
| AstraZeneca | 30 | $31,046 |
| GE HealthCare | 5 | $13,459 |
| Genentech USA, Inc. | 4 | $4,467 |
| Genentech, Inc. | 3 | $3,563 |
| Daiichi Sankyo Inc. | 1 | $3,000 |
| Eli Lilly | 2 | $2,825 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,663 |
| F. Hoffmann-la Roche AG | 3 | $911 |
| Gilead(2 entities) | 6 | $167 |
| Recordati_rare_diseases_inc. | 1 | $152 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $143 |
| AbbVie | 6 | $133 |
| Pfizer | 4 | $77 |
| Johnson & Johnson | 5 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Secura Bio, Inc. | 4 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $40 |
| Novartis | 2 | $36 |
| Bristol Myers Squibb | 2 | $31 |
| Springworks Therapeutics, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $25 |
| Sanofi | 1 | $25 |
| EMD Serono, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Biocompatibles, Inc. | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,389 in reported general payments places this provider in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 34 | $543,609 |
| EliquisApixaban | 12 | $6,783 |
| Anastrozole | 13 | $460 |
| Prochlorperazine Maleate | 32 | $350 |
| Ondansetron OdtOndansetron | 28 | $339 |
| Ondansetron Hcl | 18 | $281 |
| Gabapentin | 23 | $235 |
| Prednisone | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $31,046 | $543,60934 claims |
| PfizerEliquis | $77 | $6,78312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Memphis
- Ugochi OguMemphis$250K
- Patricia Adams-GravesMemphis$168K
- Donald GravenorMemphis$166K
- Aleksandar JankovMemphis$163K
- Brion RandolphMemphis$162K
- Kenneth AtagaMemphis$157K
- Saurin ChokshiMemphis$86K
- Clyde JonesMemphis$54K
- Salil GoorhaMemphis$51K
- Muhammad RazaMemphis$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.